Geneva, Aug. 29 -- International Clinical Trials Registry received information related to the study (NCT07120425) titled 'A Study of IBI3032 in Healthy Participants' on Aug. 6.
Study Type: Interventional
Study Design:
Allocation: Randomized. Intervention model: Sequential Assignment. Primary purpose: Other. Masking: Double (Participant, Investigator).
Primary Sponsor: Fortvita Biologics (USA)Inc.
Condition:
Healthy
Intervention:
Drug: IBI3032
Recruitment Status: Not recruiting
Phase: Phase 1
Date of First Enrollment: September 1, 2025
Target Sample Size: 32
Countries of Recruitment:
United States
To know more, visit https://clinicaltrials.gov/ct2/show/NCT07120425
Published by HT Digital Content Services with permission ...